RT Journal Article
SR Electronic
T1 Is 6-minute walk distance (6MWD) associated with long-term outcomes in pulmonary arterial hypertension (PAH)? Results from SERAPHIN
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3417
VO 42
IS Suppl 57
A1 Marion Delcroix
A1 Richard Channick
A1 Nazzareno Galiè
A1 Hossein-Ardeschir Ghofrani
A1 Pavel Jansa
A1 Franck-Olivier Le Brun
A1 Sanjay Mehta
A1 Loïc Perchenet
A1 Tomás Pulido
A1 B.K.S. Sastry
A1 Olivier Sitbon
A1 Rogério Souza
A1 Adam Torbicki
A1 Gérald Simonneau
A1 Lewis Rubin
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P3417.abstract
AB Macitentan's effect on 6MWD and the association between 6MWD and the long-term outcome of PAH-related death or hospitalisation (PAHDH) were explored in SERAPHIN (NCT00660179) where 742 PAH patients were randomised to placebo, macitentan 3 or 10mg q.d. Repeated measures analysis was performed on 6MWD changes from baseline (BL) at Months 3, 6, 12. In patients with available data for 6MWD at Month 6, hazard ratios measured associations between interquartile ranges of BL 6MWD, 6MWD changes, or Month 6 values (±adjustment for significant covariates) and the risk of PAHDH from Month 6. 6MWD benefit was sustained with macitentan vs placebo over 12 months (3mg: +21.5m [95%CI 10.0–33.0]; P=0.0003 and 10mg: +25.4m [95%CI 13.8–37.0]; P<0.0001). Lower BL 6MWD and Month 6 values were associated with PAHDH risk. Absolute value at Month 6 lost its association when adjusted for BL 6MWD and sex. Neither adjusted nor non-adjusted changes in 6MWD from BL to Month 6 were associated with PAHDH risk.View this table:Association of 6MWD with PAHDH risk